you don't really realize how correct you are..Every time this sells off, an
article comes out to proclaim how valuable this is..this is so supported by
the hedge funds media machines..Once the new year is behind us, they
will start to divest themselves, and they will take short positions, and then
you'll start to see the news of value change.
And we are both invested in INSM,,,now what does that tell you? One of these days we are gonna be
on the winning end of something....It's a good thing the bears don't play basketball...
Iplex and Increlex are not the same drug. Not even close. The legal settlement was in regard to the
method of production that caused both drugs to be made. INSM infringed on the methodology that
Tercica owned the patten to, and therefor is not permitted to be produced for the indication that IPLEX
was approved for.
Look at this stock this morning,,,and you'll see what following Cramer can get for you.
Jim Cramer ranked this stock a Sell. The stock’s 52-week high is $31.00, and its 52-week low is $12.78. Cramer did not recommend OncoMed
I agree with you as far as the state of the markets..I think the funds, and institutional investors are going
to continue to add to their positions going into the year end because they want the hot names on their
year end recaps..I also think a 20% correction is not out of the question. I think the market is priced for
perfection, and at best next year is being forcasted at a 5% earnings growth rate..If that is true, which by
the way might not be (most forcasts looking forward are too aggressive..This year was forcast at 10%
and is only producing 5) this is going to make 2014 very challenging. As far as INSM is concerned, my
position is pretty clear. I do think we could have some stock value fluxuations, and that to me is normal.
I do expect we hear some good news within the next 90 days.
I agree with you...this will go to 1200.00 by Christmas,,,every institutional buyer out there
wants to have this in their yearend statement...but after that...by January 10,,this will
lose a large position of it's gleam...
I'm willing to take this dividend for the next 24 months while this moves up 50%...better than taking
on the risk of the S&P for a shot at 4%,,and no dividend////
You're entitled to a space on this board, but you're not entitled to your own FACTS. When you do
things like this, you just make yourself out to be less than credible, but you're mom has already
told you that, so go back to making those juicy burgers...
This post covered the entirety of what we saw today...Read it...Read it all...
He has done this to INO, CPRX, OSIR, and now INSM among others.
So why use a semi-quantitative culture scale. Answer is simple. Fartstain is not a scientist. Mycobacterial species especially M. Avium intracellulare and other non tuberculosis mycobacteria are obligate intracellular (as the name implies) bacteria that are SLOW growing. Since they are obligate intracellular, they don't grow like e. coli or normal bacteria that don't need a human host.
In the lab my lab works with mycobacterium leprae. You have to use polymerase chain reaction (PCR) to look for ribosomal RNA of mycobacteria species, since you can't really culture it by itself, you have to use a semi quantitative scale to see the growth of the pathogen in the sputum.
Seriously, AF is not a scientist, nor should he be doing reports on any biotech companies. He really needs to get off his high horse of half-truths, and learn something fully before he reports it.
He is hurting many people with his GARBAGE who are trying to invest their money in good companies with promise. You don't ever see him go after Pfizer or Roche or Gilead or Celgene do you? I am sure they have the same problems with study design, etc, because NO WAY scientific studies in humans can be perfect. He gave up on ACAD once it had too much momentum and he couldn't get his profiteer followers who give him millions for his blasphemy any more profits.
He's disgusting, goes after the small caps because he, and his short followers can, harms innocent people.
Take a look in the mirror you #$%$ piece of non-scientific dog vomit before you go after CPRX or INSM, or INO, companies that unlike you ARE trying to help people
I talked to IR today,,and the company can not respond to this under any
circumstances until after earnings are released. This is a standard quite
period that every company has to adhere to, so even if they wanted to make
a statement, they are prevented from doing so. This writer had to know that,
and intentionally gave a vague indication that the company wasn't responding.
I ask myself if this was an article written to accomplish a move down in the
stock price to facilitate investors aligned with this writer who knows he's
able to get away with this. I would worry even more if the company did respond.
That would say they aren't observing protocol, and are willing to gamble by
disobeying the law.
Sees this for what it is, and takes the opportunity to buy on this..Would anyone in their right mind think for
a minute that the FDA would be fooled by what this known enity tries to pass as scientific prowess? Is he
kidding? I wouldn't be surprised to see one of the analysts following this company to come out and re-itterate
their view. Not only is this writer calling the company a fraud, but he's attacking the credibility and integrity of
every analyst that has issued a buy position in this company. Does anyone for a second believe that if what he purports to be factual the analysts wouldn't have spotted it immediately, and issued a sell recommendation?
I am a buyer here, and might have to purchase a subscription to his column in thanks, and for comic relief.
•LAI was generally safe and well tolerated, and no unexpected adverse events were observed
•LAI administered once daily is comparable to TOBI® administered twice daily in improving
lung function, the standard of care in patients with CF chronically infected with Pa
•Patients maintained on LAI reported significantly greater improvement in their respiratory
symptoms compared with the TOBI® arm at the end of the treatment period of the study
•Patients also reported less treatment burden in the LAI arm, which is administered once daily
•LAI is an effective inhaled aminoglycoside antibiotic in the treatment of chronic Pa bron cho -
Insmed Completes Enrollment of Phase 2 Clinical Trial of ARIKACE to Treat Nontuberculous Mycobacteria Lung Disease in U.S. and Canada
Commences Scientific Advice Working Party Process With EMA for Clarity on Path Forward for ARIKACE to Treat Nontuberculous Mycobacteria Lung Disease in Europe